Anifrolumab Treatment Improves Patient-Reported Quality of Life and Decreases Disease Activity and Corticosteroid Use in Patients with Systemic Lupus Erythematosus: A Qualitative Study in Denmark
June 2024
in “
Lupus
”
Studysummary This study provides insights into systemic lupus erythematosus patients' experiences with Anifrolumab, highlighting improvements in symptoms and health-related quality of life, despite ongoing daily life impacts.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on journals.sagepub.com →